JP2018504429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504429A5 JP2018504429A5 JP2017541075A JP2017541075A JP2018504429A5 JP 2018504429 A5 JP2018504429 A5 JP 2018504429A5 JP 2017541075 A JP2017541075 A JP 2017541075A JP 2017541075 A JP2017541075 A JP 2017541075A JP 2018504429 A5 JP2018504429 A5 JP 2018504429A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- day
- composition according
- compound
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 17
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 11
- 230000000750 progressive effect Effects 0.000 claims description 10
- 201000005787 hematologic cancer Diseases 0.000 claims description 9
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 9
- 108700028369 Alleles Proteins 0.000 claims description 7
- 206010008583 Chloroma Diseases 0.000 claims description 7
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 7
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- SWWHCQCMVCPLEQ-UHFFFAOYSA-N propan-2-yl methanesulfonate Chemical compound CC(C)OS(C)(=O)=O SWWHCQCMVCPLEQ-UHFFFAOYSA-N 0.000 claims 2
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 description 53
- 238000002411 thermogravimetry Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- 239000000843 powder Substances 0.000 description 21
- 238000000113 differential scanning calorimetry Methods 0.000 description 16
- 229940126214 compound 3 Drugs 0.000 description 11
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 11
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175208A JP2023011792A (ja) | 2015-02-04 | 2022-11-01 | 治療効果のある化合物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112127P | 2015-02-04 | 2015-02-04 | |
| US62/112,127 | 2015-02-04 | ||
| PCT/US2016/016335 WO2016126798A1 (en) | 2015-02-04 | 2016-02-03 | Therapeutically active compounds and their methods of use |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180152A Division JP2021038227A (ja) | 2015-02-04 | 2020-10-28 | 治療効果のある化合物及びその使用方法 |
| JP2022175208A Division JP2023011792A (ja) | 2015-02-04 | 2022-11-01 | 治療効果のある化合物及びその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018504429A JP2018504429A (ja) | 2018-02-15 |
| JP2018504429A5 true JP2018504429A5 (https=) | 2019-03-14 |
| JP7220986B2 JP7220986B2 (ja) | 2023-02-13 |
| JP7220986B6 JP7220986B6 (ja) | 2024-02-08 |
Family
ID=55640843
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541075A Active JP7220986B6 (ja) | 2015-02-04 | 2016-02-03 | 治療効果のある化合物及びその使用方法 |
| JP2020180152A Pending JP2021038227A (ja) | 2015-02-04 | 2020-10-28 | 治療効果のある化合物及びその使用方法 |
| JP2022175208A Pending JP2023011792A (ja) | 2015-02-04 | 2022-11-01 | 治療効果のある化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180152A Pending JP2021038227A (ja) | 2015-02-04 | 2020-10-28 | 治療効果のある化合物及びその使用方法 |
| JP2022175208A Pending JP2023011792A (ja) | 2015-02-04 | 2022-11-01 | 治療効果のある化合物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10201543B2 (https=) |
| EP (1) | EP3253746A1 (https=) |
| JP (3) | JP7220986B6 (https=) |
| KR (1) | KR102628370B1 (https=) |
| CN (1) | CN107531675A (https=) |
| CA (1) | CA2975506A1 (https=) |
| IL (1) | IL253796A0 (https=) |
| WO (1) | WO2016126798A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| EP3493809B1 (en) | 2016-08-03 | 2023-08-23 | Celgene Corporation | Enasidenib for treatment of myelodysplastic syndrome |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015018060A1 (en) * | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) * | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| IL298663A (en) | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| EP3493809B1 (en) | 2016-08-03 | 2023-08-23 | Celgene Corporation | Enasidenib for treatment of myelodysplastic syndrome |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
-
2016
- 2016-02-03 CN CN201680020656.7A patent/CN107531675A/zh active Pending
- 2016-02-03 US US15/548,737 patent/US10201543B2/en active Active
- 2016-02-03 WO PCT/US2016/016335 patent/WO2016126798A1/en not_active Ceased
- 2016-02-03 CA CA2975506A patent/CA2975506A1/en not_active Abandoned
- 2016-02-03 EP EP16712552.5A patent/EP3253746A1/en not_active Withdrawn
- 2016-02-03 KR KR1020177024658A patent/KR102628370B1/ko active Active
- 2016-02-03 JP JP2017541075A patent/JP7220986B6/ja active Active
-
2017
- 2017-08-02 IL IL253796A patent/IL253796A0/en unknown
-
2018
- 2018-12-21 US US16/230,090 patent/US10434105B2/en active Active
-
2020
- 2020-10-28 JP JP2020180152A patent/JP2021038227A/ja active Pending
-
2022
- 2022-11-01 JP JP2022175208A patent/JP2023011792A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504429A5 (https=) | ||
| AU2020382214B2 (en) | Novel salt of terphenyl compound | |
| CA2863515C (en) | Pyridone derivatives | |
| JP2019142930A5 (https=) | ||
| JP2016527279A5 (https=) | ||
| JP2017537969A5 (https=) | ||
| JP2021524835A5 (https=) | ||
| JP2011515370A (ja) | ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態 | |
| KR102142797B1 (ko) | 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도 | |
| US20210309640A1 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| JP2020536893A5 (https=) | ||
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2019506392A5 (https=) | ||
| CN112839656A (zh) | 急性骨髓性白血病用抗肿瘤剂 | |
| JP5924453B2 (ja) | 二環式含窒素芳香族ヘテロ環アミド化合物 | |
| UA78801C2 (en) | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4- 1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride | |
| US11883402B2 (en) | Crystalline forms of a quinazoline compound and its hydrochloride salts | |
| KR20210024004A (ko) | Cdk4/6의 활성을 억제하기 위한 화합물의 결정 형태 및 그것의 용도 | |
| JPWO2012147832A1 (ja) | フェニルピロール誘導体の結晶 | |
| JP2026503095A (ja) | リナプラザングルレート（ｌｉｎａｐｒａｚａｎ ｇｌｕｒａｔｅ）の臭化水素酸塩の多形 | |
| WO2018115965A1 (en) | Solid forms of imidazopyrazine compounds | |
| KR102501514B1 (ko) | 2'-아미노-6-(2-아미노-6-(1-이소프로필피페리딘-4-일)-5-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 3염산염 및 이를 포함하는 약제학적 조성물 | |
| AU2023283774A1 (en) | Btological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5- yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan- 7-ol crystalline, phosphoric acid salt and its enantiomers | |
| KR20210029694A (ko) | 2'-아미노-6-(2-아미노-6-메틸피리미딘-4-일)-3'-플루오로-[2,4'-바이피리딘]-5-올 2염산염 및 이를 포함하는 약제학적 조성물 | |
| HK40116757A (zh) | 固态形式 |